Navigation Links
KJT Group Hires Director of Health Outcomes
Date:7/9/2013

HONEOYE FALLS, N.Y., July 8, 2013 /PRNewswire/ -- KJT Group, Inc. is pleased to announce the hiring of Arun Changolkar, PhD, MBA as the Director of Health Outcomes Research to its expanding life sciences research and consulting organization.

Dr. Changolkar, of Philadelphia, brings extensive academic and professional experience in health economics and outcomes research. His experience includes leadership roles in the pharmaceutical and clinical research industries. With expertise in epidemiology and statistics his project experience spans both U.S. and global healthcare in oncology, vaccines, and autoimmune disease. 

He joins KJT Group after serving in various industry positions including Director of Global Health Outcomes at Stiefel and Manager of Health Outcomes and Analytics at GlaxoSmithKline. His experience includes the design and execution of HEOR studies to support multiple global country specific successful reimbursement submissions, supporting clinical trials, and various other post-marketing observational studies to generate clinical evidence.  He also participated in and contributed to strategic pricing, global value dossier synthesis, and core value development for various pharmaceutical products. Changolkar's accomplishments include numerous abstracts in international and national scientific meetings and 11 publications in scientific journals. 

"Arun brings a very nice mix of skills and experience to KJT Group's growing Health Outcomes Practice. Having worked on both the client and vendor sides he brings strong analytic skills as well as a clear understanding of the underlying business issues that our customers face," said Kenneth Tomaszewski, PhD, MS, Founder and CEO of KJT Group.

Following the completion of his PhD, Changolkar received post-doctoral training as an Anticancer Drug Discovery Researcher at Harvard Medical School and an Epigenetics Researcher at the University of Pennsylvania in Philadelphia.

As the Director of Health Outcomes Research at KJT Group, Changolkar will work closely with KJT Group researchers and oversee the design and conduct of KJT Group's health economics and outcomes research studies.

About KJT Group: KJT Group (www.kjtgroup.com) is a full service life sciences market research and insight consultancy firm. Established in 2007, KJT Group employs nearly 50 full-time staff in New York, Pennsylvania, Texas, South Carolina and The Netherlands. KJT Group is a member of the National Council on Public Polls (NCPP), Council of American Survey Research Organizations (CASRO) and the European Society Opinion and Marketing Research (ESOMAR).


'/>"/>
SOURCE KJT Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Smart Consulting Group and The Catalyst Group Form Alliance to Supply Quality Compliance Consulting Services For the Pharmaceutical Industry
2. Knowledgent Group Inc. Applies for Patent in Chemical Information Management
3. Cellular Biomedicine Group Announces Expansion in the Osteoarthritis and Rheumatoid Arthritis Market
4. Cellular Biomedicine Group Announces Appointment of Corporate Controller
5. CTI Reports Final Results from Cooperative Group and NCI-Sponsored Trial of Brostallicin in Patients with Metastatic Triple-Negative Breast Cancer
6. The JTB Law Group Continues to Innovate with its New Video Information Series and Vivid Legal Cartoons
7. The Hemostemix Group of Companies Provides Corporate Strategy Update
8. Eurofins MWG Operon Quality Assurance Group Completes ISO Certifications for Their New Overnight Sequencing Lab
9. YouTube Channel on SEO Tips Surpasses 175,000 Views, Announces JM Internet Group
10. Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group
11. Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... 25, 2016 , ... Biohaven Pharmaceutical Holding Company Ltd. (Biohaven) ... company’s orphan drug designation request covering BHV-4157 for the treatment of Spinocerebellar Ataxia ... , Spinocerebellar ataxia is a rare, debilitating neurodegenerative disorder that is estimated ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... identity. The new Media Cybernetics corporate branding reflects a results-driven revitalization for a ... image analysis. The re-branding components include a crisp, refreshed logo and a new ...
(Date:5/23/2016)... OXFORD, England , May 23, 2016 ... Wednesday, May 25 th at 10:15 a.m. ET before ... about the role genetically engineered mosquitos can play in controlling ... known carrier of the Zika virus.      (Logo: ... genetically engineered male mosquito with a self-limiting gene. Trials in ...
(Date:5/22/2016)... ... 22, 2016 , ... Doctors in Rome say micronutrients found in certain foods ... Surviving Mesothelioma has just posted an article on the new research. Click here ... Clinical Sciences and Translational Medicine evaluated more than 150 studies on polyphenols in cancer ...
Breaking Biology Technology:
(Date:5/20/2016)... 2016  VoiceIt is excited to announce its ... By working together, VoiceIt and VoicePass will ... VoicePass take slightly different approaches to voice biometrics, ... and usability. ... partnership. "This marketing and technology partnership ...
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):